scholarly article | Q13442814 |
P50 | author | Peter Mugyenyi | Q16732954 |
Victor Musiime | Q43093872 | ||
Margaret Thomason | Q56547049 | ||
Sabrina Bakeera-Kitaka | Q60249119 | ||
Diana M Gibb | Q62738885 | ||
Lindsay Kendall | Q63630847 | ||
Ann Sarah Walker | Q90248231 | ||
Philippa Musoke | Q96163738 | ||
ARROW Trial team | Q114437775 | ||
P2093 | author name string | David Burger | |
Adeodata Kekitiinwa | |||
Kimberly Adkison | |||
Florence Odongo | |||
Wendy B Snowden | |||
P433 | issue | 8 | |
P921 | main subject | Uganda | Q1036 |
abacavir | Q304330 | ||
pharmacokinetics | Q323936 | ||
lamivudine | Q422631 | ||
P304 | page(s) | 1115-1124 | |
P577 | publication date | 2010-01-01 | |
P1433 | published in | Antiviral Therapy | Q4775353 |
P1476 | title | Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial | |
P478 | volume | 15 |
Q38723580 | Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis |
Q37866289 | Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges |
Q37731863 | Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children |
Q38771392 | Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis. |
Q36306986 | Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial |
Q42905874 | Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research |
Q37696578 | Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials |
Q36386846 | Managing HIV-infected children in a low-resource, public clinic: a comparison of nurse vs. clinical officer practices in ART refill, calculation of adherence and subsequent appointments. |
Q38855053 | Once vs twice-daily abacavir and lamivudine in African children |
Q41505058 | Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life |
Q38868724 | Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. |
Q37708677 | Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children |
Q37098376 | Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children |
Q36948138 | Population pharmacokinetics of abacavir in infants, toddlers and children |
Q30539434 | Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial |
Q44986291 | When to start, what to start and other treatment controversies in pediatric HIV infection |
Q28483158 | Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa |
Search more.